Clinical Research Trials
STUDIEN
Liste der laufenden und der abgeschlossenen klinischen Studien am Zentrum:
Efficacy and safety of cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (CagriSema s.c. mg/2.4 mg) once-weekly in participants with overweight or obesity and type 2 diabetes. (REDEFINE 2)
Efficacy and safety of cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (CagriSema s.c. mg/2.4 mg) once-weekly in participants with overweight or obesity. (REDEFINE 1)
Efficacy, safety, tolerability and quality of life of ongoing individually optimized lipid-lowering therapy with or without inclirisan (KJX839) - a randomized, placebo-controlled, double-blind multicenter phase IV study in participants with hypercholesterolemia.
Efficacy and safety of oral semiglutaide 25 mg once daily in adults with overweight or obesity. (OASIS 4)
Efficacy and safety of oral semaglutide 50 mg once daily in subjects with overweight or obesity. (OASIS 1)
Effectiveness and safety of once weekly insulin icodec used with DoseGuide versus once daily basal insulin analogues in an insulin naive type 2 diabetes population in a clinical practice setting. (ONWARDS 5)
A 26-week trial comparing the effect and safety of once weekly insulin icodec and once daily insulin degludec, both with or without non-insulin anti-diabetic drugs, in subjects with type 2 diabetes treated with basal insulin. (ONWARDS 2)
EudraCT Nr. 2018-001540-56, COPD, GlaxoSmithKline UK, Phase III (since 2019 ongoing) ME
A multi-center, randomized, double-blind, parallel-group, placebo controlled study of mepolizumab 100 mg SC as add-on treatment in participants with COPD experiencing frequent exacerbations and characterized by eosinophil levels.
Multi-center cross-sectional epidemiological study to characterize the prevalence and distribution of lipoprotein (a) levels among patients with established cardiovascular disease.
EudraCT Nr. 2017-003219-20, Diabetes, Novo Nordisk, Phase III (2018-2021) ME
Effect of semaglutide once-weekly versus insulin aspart three times daily, both as add on to metformin and optimised insulin glargine (U 100) in subjects with type 2 diabetes.
EudraCT Nr. 2017-003414-10, Obesity, Novo Nordisk, Phase III (2018-2020) ME
Effect and safety of semaglutide 2,4 mg once-weekly in subjects with overweight or obesity and type 2 diabetes.
EudraCT Nr. 2017-003436-36, Obesity, Novo Nordisk, Phase III (2018-2020) ME
Effect and safety of semaglutide 2,4 mg once-weekly in subjects with overweight or obesity.
EudraCT Nr. 2016-004965-22, Diabetes, Novo Nordisk, Phase III (2017-2018) ME
Efficacy and safety of semaglutide 1,0 mg once-weekly versus liraglutide 1,2 mg once-daily as add-on to 1-3 oral anti-diabetic drugs (OADs) in subjects with type 2 diabetes.
EudraCT Nr. 2014-005671-92, COPD, Pearl Therapeutics, Phase III (2017-2019) ME
A randomized, double-blind, multi-center, parallel group study to assess the efficacy and safety of PT010 relative to PT003 and mPT009 on COPD exacerbations over a 52-week treatment period in subjects with moderate to very severe COPD.
EudraCT Nr. 2016-003084-19, Diabetes, Novartis, Phase II (2017-2018) ME
A multi-center, randomized, double-blind, parallel-group dose-finding study to assess the effect of 3 doses of LIK066 compared to placebo or empagliflozin in type 2 diabetes mellitus patients with heart failure.
EudraCT Nr. 2015-001351-71, Diabetes, Novo Nordisk, Phase III (2015-2017) RE
Efficacy and long-term safety of oral semaglutide versus sitagliptin in subjects with type 2 diabetes.
EudraCT Nr. 2014-001540-38, Obesity, Novo Nordisk, Phase II (2015-2017) RE
Investigation of safety and efficacy of once-daily semiglutide in obese subjects without diabetes mellitus - a 52-week, randomised, double-blind, placebo-controlled, nine-armed, parallel group, multi-centre, multinational trial with liraglutide 3.0 mg as active comparator.
EudraCT Nr. 2014-001824-32, Diabetes, GlaxoSmithKline UK, Phase IV ( 2015-2017 ) ME
A long term, randomised, double blind, placebo-controlled study to determine the effect of albiglutide, when added to standard blood glucose lowering therapies, on major cardiovascular events in patients with Type 2 diabetes mellitus.
EudraCT Nr. 2014-003196-39, Diabetes, Novo Nordisk, Phase II (2015-2016) RE
Dose-finding of semaglutide administered subcutaneously once daily versus placebo and liraglutide in subjects with type 2 diabetes.
EudraCT Nr. 2014-002844-42, Diabetes, Sanofi, Phase III (2015-2016) ME
Six-month, randomized, open-label, parallel-group comparison oft the insulin analog SAR342434 to Humalog in adult patients with type 2 diabetes mellitus also using insulin glargine.
EudraCT Nr. 2014-002253-19, Asthma, GlaxoSmithKline UK, Phase III (2015) ME
A randomized, double-blind, double-dummy, parallel group, multicenter study of once daily Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder, twice daily Fluticasone Proprionate/Salmeterol 250/50 mcg Inhalation Powder, and twice daily Fluticasone Proprionate 250 mcg Inhalation Powder in the treatment of persistent asthma in adults and adolescents already adequately controlled on twice-daily inhalde corticosteroid and long-acting beta2 agonist.
EudraCT Nr. 2013-004502-26, Diabetes, Novo Nordisk, Phase III (2014-2015) RE
EudraCT Nr. 2013-004392-12, Diabetes, Novo Nordisk, Phase III (2014-2015) RE
Efficacy and safety of semaglutide once weekly versus insulin glargine once daily as add on to metformin with or without sulphonylurea in insulin-naïve subjects with type 2 diabetes.
EudraCT Nr. 2013-004297-98, COPD, GlaxoSmithKline UK, Phase III (2014-2015) ME
Study MEA117113: Mepalizumab vs. Placebo as add-on treatment for frequently exacerbating COPD patients characterized by eosinophil level.
EudraCT Nr. 2013-001473-24, Diabetes, Eli Lilly, Phase IV (2014-2015) ME
EudraCT Nr. 2013-002239-44, COPD, GlaxoSmithKline UK, Phase III (2013-2014) RE
A study to compare the addition of umeclidinium bromide (UMEC) to fluticasone furoate (FF)/vilanterol (VI), with placebo plus FF/VL in subjects with Chronic Obstructive Pulmonary Disease (COPD).
EudraCT Nr. 2006-003622-29, Cardiovascular Disease, Bayer, Phase III (2008-2017) RE
The ARRIVE Study (Aspirin to Reduce Risk of Initial Vascular Events) - A Randomized, Double-Blind, Placebo Controlled, Multicenter, Parallel Group Study to Assess the Efficacy (Reduction of Cardivascular Disease Events) and Safety of 100 mg Enteric-Coated Acetylsalicyl Acid in Patients at Moderate Risk of Cardiovascular Disease.
EudraCT Nr. 2008-004104-31, Chronic heart failure, Novartis, Phase III (2009-2015) RE
A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of both aliskiren monotherapy and aliskiren/enalapril combination therapy compared to enalapril monotherapy, on morbidity and mortality in patients with chronic heart failure (NYHA Class II-IV).
PraCMan, University of Heidelberg, (2011-2013) RE
Primary care practice-based care management for chronically ill patients.
EudraCT-Nr. 2012-001870-27, COPD, GlaxoSmithKline UK, Phase III (2013) RE
A randomized, double-blind, parallel group study to evaluate the efficacy and safety of fluticasone propionate/salmeterol 250/50mcg twice-daily plus GSK573719 Inhalation Powder 62.5mcg once-daily or GSK573719 Inhalation Powder 125mcg once-daily in subjects with COPD.
EudraCT Nr. 2008-002199-88, Diabetes, Novo Nordisk, Phase III (2011-2013) RE
Effect of liraglutide on body weight in overweight or obese sujects with type 2 diabetes. A 56 week randomised, double-blind, placebo-controlled, three armed parallel group, multi-centre, multinational trial with a 12 week observational follow up period.
EudraCT Nr. 2010-021560-15, Diabetes, Novo Nordisk, Phase III (2011-2012) RE
A 26 week randomised, parallel three-arm, open-label, multi-centre, multinational treat-to-target trial comparing fixed ratio combination of insulin degludec and liraglutide versus insulin degludec or liraglutide alone in subjects with type 2 diabetes treated with 1-2 oral anti-diabetic drugs.
EudraCT Nr. 2010-021800-72, COPD, GlaxoSmithKline UK, Phase III (2011-2012) RE
A multicenter trial comparing the efficacy and safety of GSK573719/GW642444 with GW642444 and with tiotropium over 24 weeks in sujects with COPD.
EudraCT Nr. 2011-000518-21, Diabetes, Novartis, Phase IV (2011-2012) RE
Cross-over study to assess the difference in fasting plasma glucose (FPG) between vildagliptin (Galvus®/Eucreas®) and sitagliptin (Januvia®/Janumet®) after two weeks (FPG-VISIT).
EudraCT Nr. 2009-010913-59, Diabetes, Sanofi-Aventis, Phase IV (2011-2012) RE
Health Assessment, Patient treatment satisfaction and Quality-of-Life in insulin-naive type 2 diabetes Patients uncontrolled on OHA treatment initiating basal insulin therapy with either insulin gl...
EudraCT Nr. 2008-007831-41, Hypertension, Novartis, Phase IV (2009-2010) RE
A twelve-week, randomized, double-blind, parallel group study to evaluate th prolonged efficacy and safety of aliskiren 300 mg compared to telmisartan 80 mg in mild to moderate hypertensive patients.
getABI, epidemiological trial, (2002-2008) RE
German epidemiological trial on ankle brachial index for elderly patients in family practice to dedect peripheral arterial disease, significant marker for high mortality.
Efficacy and safety of semaglutide once-weekly versus placebo as add-on to basal insulin alone or basal insulin in combination with metformin in subjects with typ 2 diabetes.
EudraCT Nr. 2013-003075-35, COPD, GlaxoSmithKline UK, Phase III (2014-2015) ME
A phase III, 52 week, randomized, double-blind, 3-arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF/UMEC/VI with the fixed dose dual combinations of FF/VI and UMEC/VI, all administered once-daily in the morning via a dry powder inhaler in subjects with chronic obstructive pulmonary disease.
A phase III, 52 week, randomized, double-blind, 3-arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF/UMEC/VI with the fixed dose dual combinations of FF/VI and UMEC/VI, all administered once-daily in the morning via a dry powder inhaler in subjects with chronic obstructive pulmonary disease.
EudraCT Nr. 2013-004392-12, Diabetes, Novo Nordisk, Phase III (2014-2015) RE
Efficacy and safety of semaglutide once weekly versus insulin glargine once daily as add on to metformin with or without sulphonylurea in insulin-naïve subjects with type 2 diabetes.
EudraCT Nr. 2013-004297-98, COPD, GlaxoSmithKline UK, Phase III (2014-2015) ME
Study MEA117113: Mepalizumab vs. Placebo as add-on treatment for frequently exacerbating COPD patients characterized by eosinophil level.
EudraCT Nr. 2013-001473-24, Diabetes, Eli Lilly, Phase IV (2014-2015) ME
An individualized treatment approach for older patients: A randomized, controlled study in type 2 diabetes mellitus.
EudraCT Nr. 2013-002239-44, COPD, GlaxoSmithKline UK, Phase III (2013-2014) RE
A study to compare the addition of umeclidinium bromide (UMEC) to fluticasone furoate (FF)/vilanterol (VI), with placebo plus FF/VL in subjects with Chronic Obstructive Pulmonary Disease (COPD).
EudraCT Nr. 2006-003622-29, Cardiovascular Disease, Bayer, Phase III (2008-2017) RE
The ARRIVE Study (Aspirin to Reduce Risk of Initial Vascular Events) - A Randomized, Double-Blind, Placebo Controlled, Multicenter, Parallel Group Study to Assess the Efficacy (Reduction of Cardivascular Disease Events) and Safety of 100 mg Enteric-Coated Acetylsalicyl Acid in Patients at Moderate Risk of Cardiovascular Disease.
EudraCT Nr. 2008-004104-31, Chronic heart failure, Novartis, Phase III (2009-2015) RE
A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of both aliskiren monotherapy and aliskiren/enalapril combination therapy compared to enalapril monotherapy, on morbidity and mortality in patients with chronic heart failure (NYHA Class II-IV).
PraCMan, University of Heidelberg, (2011-2013) RE
Primary care practice-based care management for chronically ill patients.
EudraCT-Nr. 2012-001870-27, COPD, GlaxoSmithKline UK, Phase III (2013) RE
A randomized, double-blind, parallel group study to evaluate the efficacy and safety of fluticasone propionate/salmeterol 250/50mcg twice-daily plus GSK573719 Inhalation Powder 62.5mcg once-daily or GSK573719 Inhalation Powder 125mcg once-daily in subjects with COPD.
EudraCT Nr. 2008-002199-88, Diabetes, Novo Nordisk, Phase III (2011-2013) RE
Effect of liraglutide on body weight in overweight or obese sujects with type 2 diabetes. A 56 week randomised, double-blind, placebo-controlled, three armed parallel group, multi-centre, multinational trial with a 12 week observational follow up period.
EudraCT Nr. 2010-021560-15, Diabetes, Novo Nordisk, Phase III (2011-2012) RE
A 26 week randomised, parallel three-arm, open-label, multi-centre, multinational treat-to-target trial comparing fixed ratio combination of insulin degludec and liraglutide versus insulin degludec or liraglutide alone in subjects with type 2 diabetes treated with 1-2 oral anti-diabetic drugs.
EudraCT Nr. 2010-021800-72, COPD, GlaxoSmithKline UK, Phase III (2011-2012) RE
A multicenter trial comparing the efficacy and safety of GSK573719/GW642444 with GW642444 and with tiotropium over 24 weeks in sujects with COPD.
EudraCT Nr. 2011-000518-21, Diabetes, Novartis, Phase IV (2011-2012) RE
Cross-over study to assess the difference in fasting plasma glucose (FPG) between vildagliptin (Galvus®/Eucreas®) and sitagliptin (Januvia®/Janumet®) after two weeks (FPG-VISIT).
EudraCT Nr. 2009-010913-59, Diabetes, Sanofi-Aventis, Phase IV (2011-2012) RE
Health Assessment, Patient treatment satisfaction and Quality-of-Life in insulin-naive type 2 diabetes Patients uncontrolled on OHA treatment initiating basal insulin therapy with either insulin gl...
EudraCT Nr. 2008-007831-41, Hypertension, Novartis, Phase IV (2009-2010) RE
A twelve-week, randomized, double-blind, parallel group study to evaluate th prolonged efficacy and safety of aliskiren 300 mg compared to telmisartan 80 mg in mild to moderate hypertensive patients.
getABI, epidemiological trial, (2002-2008) RE
German epidemiological trial on ankle brachial index for elderly patients in family practice to dedect peripheral arterial disease, significant marker for high mortality.
letzte Änderung 02.04.2024